MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:12Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 27:		Line 27:
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.		\| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.
	\| counseling = Contraindicated with any nitrate. Less visual side effect than sildenafil/vardenafil (higher PDE5 vs PDE6 selectivity). Daily dosing provides continuous coverage — useful for spontaneity and BPH symptoms.		\| counseling = Contraindicated with any nitrate. Less visual side effect than sildenafil/vardenafil (higher PDE5 vs PDE6 selectivity). Daily dosing provides continuous coverage, useful for spontaneity and BPH symptoms.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Avanafil]], [[Sildenafil]], [[Vardenafil]]		\| seealso = [[Avanafil]], [[Sildenafil]], [[Vardenafil]]

MDElliottMD: Create Tadalafil scaffold

2026-05-15T15:30:24Z

Create Tadalafil scaffold

New page

{{MedTemplate
| generic = Tadalafil
| brand = Cialis, Adcirca
| classes = PDE5 Inhibitor
| uses = <vote slug="erectile-dysfunction-use">Erectile dysfunction</vote>, <vote slug="bph-use">BPH</vote>, <vote slug="pulmonary-hypertension-use">Pulmonary arterial hypertension</vote>
| starting_dose = 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH
| preparations = 2.5, 5, 10, 20 mg tabs
| fda_max = 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH)
| routes = Oral
| onset = 30 min
| duration = Up to 36 h ("the weekend pill")
| halflife = ~17.5 h
| bioavailability = Reasonable (not formally established as a percentage)
| pregnancy = Category B
| legal = Rx-only in US
| mechanism = Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing.
| intro = Tadalafil's distinguishing feature is its long half-life (~17.5 h) and usable duration up to 36 h, hence "the weekend pill." It is the only PDE5 inhibitor FDA-approved for daily use, both for ED and for BPH. 5 mg daily often provides better continuous coverage than 20 mg PRN.
| indications =
| dosing =
| effects =
| pk_absorption = Oral; not affected by food (vs sildenafil).
| pk_distribution = Plasma protein binding ~94%.
| pk_metabolism = Hepatic via CYP3A4.
| pk_elimination = Fecal and renal as metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.
| counseling = Contraindicated with any nitrate. Less visual side effect than sildenafil/vardenafil (higher PDE5 vs PDE6 selectivity). Daily dosing provides continuous coverage — useful for spontaneity and BPH symptoms.
| anecdotes =
| seealso = [[Avanafil]], [[Sildenafil]], [[Vardenafil]]
| references = <references/>
}}

[[Category:PDE5 Inhibitors]]
[[Category:Medicines]]

Tadalafil - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Create Tadalafil scaffold